

Beyfortus™ (Nirsevimab) Safety & Managing Adverse Reactions in the Community Setting

According to the [National Advisory Committee on Immunization \(NACI\)](#) and [Ontario Ministry of Health](#), Beyfortus™ is safe for most infants.

RSV prevention products, including the monoclonal antibody or vaccine, may be associated with mild side effects that typically resolve within a few days. Common side effects of Beyfortus™ (Nirsevimab) include localized redness, swelling and/or pain at the injection site. Other mild side effects include rash and low-grade fever.

Severe reactions, including hives (urticaria), swelling of the mouth or throat (angioedema), difficulty breathing, wheezing or shortness of breath (dyspnea), high fever (pyrexia), seizures, or any other serious symptoms, require immediate assessment at the nearest emergency department.

Offering RSV immunization in community settings relies on the midwife's knowledge, skills, and clinical judgment. Health care providers administering immunizations must be knowledgeable about the signs and symptoms of adverse reactions and possess the necessary skills to manage them appropriately. If planning to administer Beyfortus™ (Nirsevimab) under a medical directive, refer to established protocol(s) for guidance on appropriate actions to take in the event of an adverse reaction.

For more comprehensive information on immunizations, visit the [Canadian Immunization Guide](#). To learn more about vaccine safety, including the management of anaphylaxis and other adverse reactions, refer to the section: [Anaphylaxis and other acute reactions following vaccination](#). Note: this section provides essential information on:

- [post-vaccination observation](#)
- [anaphylaxis management kits*](#)
- basic steps for [managing anaphylaxis in a community setting](#), and
- a [Table](#) detailing the dosage of intramuscular epinephrine based on age or weight.

*Anaphylaxis management kits should be readily available wherever vaccines are administered. Never administer an immunization without having an anaphylaxis management kit immediately available.

After immunization, be sure to inform parents about possible side effects and when they should page, visit the nearest emergency department, or call 911.

For specific resources on RSV prevention products, including the monoclonal antibody or vaccine, visit:

Public Health Agency of Canada: [Respiratory syncytial virus \(RSV\) vaccines](#)

- Includes key information on [authorized preparations](#) in Canada, [efficacy and effectiveness](#), vaccination guidelines for [specific populations](#), administration practices, [storage requirements](#), safety and potential [adverse events](#).

National Advisory Committee on Immunization (NACI): [Statement on the prevention of respiratory syncytial virus disease in infants](#)

- Provides comprehensive information on RSV prevention products, including a comparison [table](#) of products authorized for use in Canada, [vaccine efficacy](#), [concurrent administration](#) with other vaccines, [product safety](#), as well as [contraindications and precautions](#).

For detailed information on Beyfortus™ (Nirsevimab) including contraindications and precautions, please refer to the [product monograph](#).